Haizheng Pfizer international production base officially put into production to create high-end generic drugs

Mr Xiao Weihong, chief executive officer of Haizheng Pfizer Pharmaceutical Co., Ltd., presented the first box of drugs put into production to the parent company, Haizheng Pfizer Fuyang production base, an international standard made in China, successfully passed the new GMP certification of the State Food and Drug Administration in May this year, and became the GMP training base of the food and drug audit and inspection center of the State Food and drug administration As a (GMP) training base, Fuyang production base will provide practice site for inspectors of new GMP certification, become a technical exchange platform between drug regulatory authorities and drug manufacturing enterprises, and provide information and support for the government to formulate policies on drug quality standards During the preparation of the production base, Haizheng pharmaceutical has laid a solid foundation in the base, plant, equipment and other hardware Its main production equipment is from the world's leading first-class brands, such as Bosch, GEA, uhlmaan, IMA, fette, etc Based on good hardware conditions, the quality management of Fuyang production base also complies with Pfizer global quality system standard (PQS) PQS standard is the highest standard in the field of global pharmaceutical production, which means that the production base has the level to supply the global market In terms of production technology, the configuration level of the production base is very high For example, the injection production line can realize the advanced technologies such as IPC automatic adjustment system, ALUs automatic feeding and unloading system, automatic online cleaning, online sterilization, online continuous environmental monitoring, etc., so as to truly realize the automatic and efficient production At the same time, the new concept of minimizing human intervention is realized at the design level, such as full isolation technology used in sterile product production workshop, online automatic loading detection technology, etc., which can greatly reduce the quality risk caused by human error Among them, the application of aseptic isolation technology is also in a leading position in China In the future, Haizheng huirui Fuyang production base will accept the overall audit of Pfizer's global quality department every year, and will keep pace with Pfizer in the development of aseptic technology, slow controlled release technology, pat technology and other advanced technology fields, and provide high-quality brand generic drugs for Chinese market and global market with Pfizer's global quality system standard Based on China and looking at the world Two years ago, haizhenghuirui established the international development plan of "based on China and enter the world" at the beginning of its establishment It is committed to supporting China's medical and health reform by providing cost-effective brand generic drugs, promoting and improving the independent innovation ability of China's pharmaceutical industry, especially improving the preparation technology, promoting the development of China's finished drugs and high value-added products, and serving China Pharmaceutical companies make contributions to the international mainstream market Up to now, several products of the oral solid preparation production line of Haizheng Pfizer Fuyang production base have submitted anda (generic drug application) to the FDA of the United States In the near future, it will also receive the FDA's on-site certification review, which means that the internationalization process of Haizheng Pfizer will be substantially promoted soon Mr Xiao Weihong, CEO of Haizheng Pfizer, said that the official production of the international production base of Haizheng Pfizer is an important and far-reaching step to realize the company's mission of "meeting the needs of the most people for healthy life" At the same time, quality comes from design Good quality drugs are produced and designed In the next step, the company will continue to improve Fuyang production base, accelerate the construction of independent R & D system, rely on the strong R & D resources, rich R & D experience and advanced R & D system of the two parent companies, establish and improve the R & D level of high-end non patent drugs as soon as possible, and lay a solid foundation for the long-term development of the company director According to reports, the production base of Haizheng huirui Fuyang can produce tablets, hard capsules, freeze-dried powder injection of anti-tumor drugs, small volume injection of anti-tumor drugs, Peinan powder injection and other products at the same time It is estimated that the annual production capacity of the anti-tumor drug production line is 10 million bottles, the annual production capacity of the Peinan powder injection production line is 10 million bottles, and the annual production capacity of the oral preparation production line is 1.5 billion tablets / capsule Market positioning: the middle city develops Pfizer's academic advantages Senior leaders of Haizheng Pfizer received a media interview at the press conference Ding Xiangyuan's editor interviewed Mr Zhang Heping, vice president of national market strategy and business development of Haizheng Pfizer Pharmaceutical Co., Ltd for the future academic marketing strategy of Haizheng Pfizer Mr Zhang Heping mentioned that in the past, foreign enterprises have basically positioned the market in the first and second tier cities, while state-owned enterprises are used to operating in more basic level markets such as the sixth and seventh tier cities Third tier to fifth tier cities have always been in a position where foreign enterprises can't come down and state-owned enterprises can't go up Haizhenghuirui hopes to open the mid city market with high quality and high price domestic brand non patent drugs, and provide more treatment options for doctors and patients At the same time, Mr Zhang Heping also said that Pfizer, the parent company of Haizheng Pfizer, has a strong academic marketing strength and a lot of platforms to meet the academic needs of doctors Haizheng Pfizer will continue to carry forward the academic advantages of Pfizer, and at the same time, it will build some academic platforms based on the local, more innovative, to help doctors understand and master the characteristics and applications of drugs On May 18, 2012, at the Sino US economic and trade cooperation forum held in Los Angeles, Haizheng pharmaceutical and its wholly-owned subsidiary, Haizheng Hangzhou company, signed the joint venture agreement with Pfizer Luxembourg company, a subsidiary of Pfizer On September 13, 2012, Haizheng Pfizer Pharmaceutical Co., Ltd was officially established Haizheng Pfizer is a Sino foreign joint venture pharmaceutical company that independently operates the R & D, production and marketing of brand non patent drugs, in which Haizheng with Chinese capital accounts for 51% and Pfizer with foreign capital accounts for 49% In essence, it is a joint venture limited company controlled by Chinese local enterprises Haizheng Pfizer is the largest pharmaceutical cooperation project in China and the United States, with a total investment of US $295 million and a registered capital of US $250 million The production base is located in Fuyang City, Zhejiang Province It has the most advanced production equipment in the world It costs 1.5 billion yuan to build six internationally advanced production lines, including oral preparations and lyophilized preparations The products cover many fields, such as tumor, antibiotic, cardiovascular, diabetes, hormone, spirit, immune transplantation, etc Since 2013, Haizheng huirui has more than 80 products, including 7 products injected by its parent company Pfizer and more than 70 products injected by Haizheng Since then, there will be other new products on the market Haizheng Pfizer business operation center is located in Shanghai, and has realized sales since the beginning of 2013 As of the first quarter of 2014, the company has more than 2000 employees In the first year of operation (referring to fiscal year 2013), the company achieved revenue of RMB 4.319 billion It is estimated that by 2020, the sales network will cover 95% of the country's top three hospitals, 90% of the second level hospitals and 75% of the first level hospitals At the same time, following its international development strategy, it plans to export products to multiple countries and regions